160 related articles for article (PubMed ID: 31809366)
1. Postmarketing Surveillance of Pregnancy Outcomes With Dolutegravir Use.
Crawford M; van Wyk J; Aboud M; Vannappagari V; Romach B; Curtis L; Wynne B; de Ruiter A; Smith K; Payvandi N
J Acquir Immune Defic Syndr; 2020 Jan; 83(1):e2-e5. PubMed ID: 31809366
[No Abstract] [Full Text] [Related]
2. The promise of paediatric dolutegravir.
Golin R; Samuel JM; Phelps BR; Persaud U; Malati CY; Siberry GK
J Int AIDS Soc; 2021 Jan; 24(1):e25660. PubMed ID: 33522081
[No Abstract] [Full Text] [Related]
3. Abacavir/dolutegravir/lamivudine single-tablet regimen: a review of its use in HIV-1 infection.
Greig SL; Deeks ED
Drugs; 2015 Apr; 75(5):503-14. PubMed ID: 25698454
[TBL] [Abstract][Full Text] [Related]
4. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
[TBL] [Abstract][Full Text] [Related]
5. Fetal biometry following in-utero exposure to dolutegravir-based or efavirenz-based antiretroviral therapy.
Banda FM; Powis KM; Sun S; Makhema J; Masasa G; Yee LM; Jao J
AIDS; 2020 Dec; 34(15):2336-2337. PubMed ID: 32910067
[No Abstract] [Full Text] [Related]
6. Pharmacokinetics and Safety of the Integrase Inhibitors Elvitegravir and Dolutegravir in Pregnant Women With HIV.
Nguyen B; Foisy MM; Hughes CA
Ann Pharmacother; 2019 Aug; 53(8):833-844. PubMed ID: 30739498
[No Abstract] [Full Text] [Related]
7. Dolutegravir pharmacokinetics in pregnant and postpartum women living with HIV.
Mulligan N; Best BM; Wang J; Capparelli EV; Stek A; Barr E; Buschur SL; Acosta EP; Smith E; Chakhtoura N; Burchett S; Mirochnick M;
AIDS; 2018 Mar; 32(6):729-737. PubMed ID: 29369162
[TBL] [Abstract][Full Text] [Related]
8. Low-cost urine tenofovir assay to triage dolutegravir resistance testing.
Martinson T; Nwogu-Attah J; Spinelli M; Gandhi M
Lancet HIV; 2024 May; 11(5):e282-e283. PubMed ID: 38461845
[No Abstract] [Full Text] [Related]
9. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.
Zash R; Makhema J; Shapiro RL
N Engl J Med; 2018 Sep; 379(10):979-981. PubMed ID: 30037297
[No Abstract] [Full Text] [Related]
10. Rollout of dolutegravir-based antiretroviral therapy in sub-Saharan Africa and its public health implications.
Wilson HI; Mapesi H
Pan Afr Med J; 2020; 37():243. PubMed ID: 33552361
[No Abstract] [Full Text] [Related]
11. [Dolutegravir in acute HIV-1 infection: first reported case].
Garibaldi F; Pozzati M; Rodriguez C; Cecchini D
Rev Esp Quimioter; 2019 Aug; 32(4):387-389. PubMed ID: 31298515
[No Abstract] [Full Text] [Related]
12. The promise of paediatric dolutegravir in Zimbabwe.
Makoni M
Lancet HIV; 2022 Sep; 9(9):e603-e604. PubMed ID: 36055292
[No Abstract] [Full Text] [Related]
13. Dolutegravir drug-resistance monitoring in Africa.
Kouamou V; Inzaule S; Manasa J
Lancet HIV; 2021 Nov; 8(11):e664-e666. PubMed ID: 34735801
[No Abstract] [Full Text] [Related]
14. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
15. Compelling evidence for unconditional shift to dolutegravir.
Steegen K; Hans L
Lancet HIV; 2022 Aug; 9(8):e523-e524. PubMed ID: 35905750
[No Abstract] [Full Text] [Related]
16. Dolutegravir-induced hyperglycaemia in a patient living with HIV.
McLaughlin M; Walsh S; Galvin S
J Antimicrob Chemother; 2018 Jan; 73(1):258-260. PubMed ID: 29077869
[No Abstract] [Full Text] [Related]
17. HIV-1 diversity and the implementation of integrase strand-transfer inhibitors as part of combination antiretroviral therapy.
Mikasi SG; Ikomey GM; Obasa AE; Cloete R; Jacobs GB
S Afr Med J; 2020 Aug; 110(9):13071. PubMed ID: 32880259
[No Abstract] [Full Text] [Related]
18. Dolutegravir for children with HIV-associated tuberculosis.
Meyers T; Krogstad P
Lancet HIV; 2022 Sep; 9(9):e599-e600. PubMed ID: 35868340
[No Abstract] [Full Text] [Related]
19. Dolutegravir with boosted darunavir as treatment simplification for treatment-experienced HIV patients with multiple mutations.
Paparizos V; Vasalou V; Kourkounti S
Int J STD AIDS; 2019 Oct; 30(12):1214-1215. PubMed ID: 31775586
[No Abstract] [Full Text] [Related]
20. Is resistance to dolutegravir possible when this drug is used in first-line therapy?
Mesplède T; Wainberg MA
Viruses; 2014 Aug; 6(9):3377-85. PubMed ID: 25166745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
